ICH Publishes New Guidance on Pediatric Clinical Trials and Genomic DataPublished on December 21, 2017
Author: Bhavesh Patel, C. Chem.
The ICH has published and adopted two new guidance documents relating to drug development.
The first document, an addendum to ICH E:11 entitled “Clinical Investigation of Medicinal Products in the Pediatric Population”, addresses new scientific and technical knowledge advances in pediatric drug development. The document updates certain aspects of the ICH E11 Guideline adopted in 2000. The amendment includes guidance on ethical considerations, age classifications and subgroups for children, pediatric formulations and guidance on extrapolation in pediatric drug development and trial design.
The second document, entitled “Guideline on Genomic Sampling and Management of Genomic Data”, addresses how genomic data should be collected in clinical trials and other studies to accord with certain methodologies during drug development and throughout the product life cycle. The guideline also covers the storage and retention of genomic samples.
We wish all our Blog Readers Happy Holidays!
Artificial Intelligence – Revolutionizing the Healthcare Industry
What is Artificial Intelligence? Artificial intelligence (AI) is a broad term for a category of algorithms and models that perform tasks and exhibit behaviors such as...
Technology Continues to Transform Healthcare and the Regulatory World
Introduction: Digital health solutions are advancing rapidly in the field of diagnostics, emergency response, hospital management. As the goal of individuals shifts more...
Rare Diseases and Orphan Drugs Regulatory Framework in Canada: Recent Initiatives by Government of Canada
What are Rare Diseases and How do They Affect Canadians? According to Health Canada, rare diseases are life-threatening, debilitating, or serious and chronic conditions that...